https://doi.org/10.4081/itjm.2024.1829

Sodium-glucose cotransporter 2 inhibition in patients with liver cirrhosis and diabetes: a possible role in ascites control?

Vol. 18 No. 4 (2024)
Published: 12 November 2024
Ascites, decompensated liver cirrhosis, sodium-glucose cotransporter 2 inhibitors, gliflozins, diabetes mellitus
Abstract Views: 614
PDF: 128
SUPPLEMENTARY MATERIAL: 63
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Aurelio Seidita
https://orcid.org/0000-0003-4080-2641
Unit of Internal Medicine, “V. Cervello” Hospital, Ospedali Riuniti “Villa Sofia-Cervello”, Palermo; Department of Health Promotion Sciences, Maternal and Infant Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo; Institute for Biomedical Research and Innovation (IRIB), National Research Council (CNR), Palermo, Italy.
Francesca Mandreucci
Unit of Internal Medicine, “V. Cervello” Hospital, Ospedali Riuniti “Villa Sofia-Cervello”, Palermo; Department of Health Promotion Sciences, Maternal and Infant Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, Italy.
Mirco Pistone
Unit of Internal Medicine, “V. Cervello” Hospital, Ospedali Riuniti “Villa Sofia-Cervello”, Palermo; Department of Health Promotion Sciences, Maternal and Infant Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, Italy.
Silvia Calderone
https://orcid.org/0009-0008-4004-0150
Unit of Internal Medicine, “V. Cervello” Hospital, Ospedali Riuniti “Villa Sofia-Cervello”, Palermo; Department of Health Promotion Sciences, Maternal and Infant Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, Italy.
Alessandra Giuliano
https://orcid.org/0000-0002-9423-5462
Unit of Internal Medicine, “V. Cervello” Hospital, Ospedali Riuniti “Villa Sofia-Cervello”, Palermo; Department of Health Promotion Sciences, Maternal and Infant Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, Italy.
Marta Chiavetta
Unit of Internal Medicine, “V. Cervello” Hospital, Ospedali Riuniti “Villa Sofia-Cervello”, Palermo; Department of Health Promotion Sciences, Maternal and Infant Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, Italy.
Lydia Giannitrapani
Department of Health Promotion Sciences, Maternal and Infant Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo; Institute for Biomedical Research and Innovation (IRIB), National Research Council (CNR), Palermo; Unit of Internal Medicine, University Hospital of Palermo, Italy.
Roberto Citarrella
Department of Health Promotion Sciences, Maternal and Infant Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo; Unit of Internal Medicine, University Hospital of Palermo, Italy.
Maurizio Soresi
Department of Health Promotion Sciences, Maternal and Infant Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo; Unit of Internal Medicine, University Hospital of Palermo, Italy.
Anna Licata
https://orcid.org/0000-0003-0383-6121
Department of Health Promotion Sciences, Maternal and Infant Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo; Unit of Internal Medicine, University Hospital of Palermo, Italy.
Antonio Carroccio
Unit of Internal Medicine, “V. Cervello” Hospital, Ospedali Riuniti “Villa Sofia-Cervello”, Palermo; Department of Health Promotion Sciences, Maternal and Infant Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, Italy.
Stella Compagnoni
stella.compagnoni.2011@gmail.com
https://orcid.org/0000-0002-3646-8225
Unit of Internal Medicine, “V. Cervello” Hospital, Ospedali Riuniti “Villa Sofia-Cervello”, Palermo, Italy.

The aim of this brief report is to evaluate sodium-glucose cotransporter 2 inhibitors (SGLT2-I) effects on patients with both refractory ascites and type 2 diabetes mellitus (T2D). We consecutively recruited all the diabetic patients with refractory ascites due to decompensated liver cirrhosis admitted between February and May 2023 at the Internal Medicine Unit of the University Hospital of Palermo. Clinical and laboratory data were collected after starting SGLT2-I therapy. SGLT2-I use was associated with a reduction/resolution of ascites and with an improvement in serum albumin and sodium levels and estimated glomerular filtration rate. SGLT2-I might represent a valid therapeutic option in the treatment of patients with refractory ascites and T2D, as already hypothesized by other research groups.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

PlumX Metrics

PlumX Metrics  provide insights into the ways people interact with individual pieces of research output (articles, conference proceedings, book chapters, and many more) in the online environment. Examples include, when research is mentioned in the news or is tweeted about. Collectively known as PlumX Metrics, these metrics are divided into five categories to help make sense of the huge amounts of data involved and to enable analysis by comparing like with like.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
Hasan FM, Alsahli M, Gerich JE. SGLT2 inhibitors in the treatment of type 2 diabetes. Diabetes Res Clin Pract 2014;104:297-322. DOI: https://doi.org/10.1016/j.diabres.2014.02.014
Usman MS, Siddiqi TJ, Anker SD, et al. Effect of SGLT2 inhibitors on cardiovascular outcomes across various patient populations. J Am Coll Cardiol 2023;81:2377-87. DOI: https://doi.org/10.1161/circ.148.suppl_1.14614
Vaduganathan M, Docherty KF, Claggett BL, et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet 2022;400:757-67. DOI: https://doi.org/10.1016/S0140-6736(22)01429-5
Herrington WG, Staplin N, Wanner C, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med 2023;388:117-27. DOI: https://doi.org/10.1056/NEJMoa2204233
Bauersachs J, Soltani S. Heart failure: update of the ESC 2023 guidelines. Herz 2023;49:19-21. [Article in German]. DOI: https://doi.org/10.1007/s00059-023-05221-2
Maxson R, Starr J, Sewell J, Lyas C. SGLT2 inhibitors to slow chronic kidney disease progression: a review. Clin Ther 2024;46:e23-8. DOI: https://doi.org/10.1016/j.clinthera.2023.10.014
Zhou P, Tan Y, Hao Z, et al. Effects of SGLT2 inhibitors on hepatic fibrosis and steatosis: a systematic review and meta-analysis. Front Endocrinol 2023;14:1144838. DOI: https://doi.org/10.3389/fendo.2023.1144838
Montalvo-Gordon I, Chi-Cervera LA, García-Tsao G. Sodium-glucose cotransporter 2 inhibitors ameliorate ascites and peripheral edema in patients with cirrhosis and diabetes. Hepatology 2020;72:1880-2. DOI: https://doi.org/10.1002/hep.31270
Saffo S, Taddei T. SGLT2 inhibitors and cirrhosis: a unique perspective on the comanagement of diabetes mellitus and ascites. Clin Liver Dis 2018;11:141-4. DOI: https://doi.org/10.1002/cld.714
Gao Y, Wei L, Zhang DD, et al. SGLT2 inhibitors: a new dawn for recurrent/refractory cirrhotic ascites. J Clin Transl Hepatol 2021;9:795-7. DOI: https://doi.org/10.14218/JCTH.2021.00418
SCORE2 working group and ESC Cardiovascular risk collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J 2021;42:2439-54. DOI: https://doi.org/10.1093/eurheartj/ehab309
Siafarikas C, Kapelios CJ, Papatheodoridi M, et al. Sodium–glucose linked transporter 2 inhibitors in liver cirrhosis: beyond their antidiabetic use. Liver Int 2024;44:884-93. DOI: https://doi.org/10.1111/liv.15851
Raza S, Osasan S, Sethia S, et al. A systematic review of sodium-glucose cotransporter 2 (SGLT2) inhibitors and sympathetic nervous system inhibition: an underrated mechanism of cardiorenal protection. Cureus 2022;14:e26313. DOI: https://doi.org/10.7759/cureus.26313
Gerdes C, Müller N, Wolf G, Busch M. Nephroprotective properties of antidiabetic drugs. J Clin Med 2023;12:3377. DOI: https://doi.org/10.3390/jcm12103377
Miyamoto Y, Honda A, Yokose S, et al. Weaning from concentrated ascites reinfusion therapy for refractory ascites by SGLT2 inhibitor. Clin Kidney J 2021;15:831-3. DOI: https://doi.org/10.1093/ckj/sfab266
Mazer CD, Hare GMT, Connelly PW, et al. Effect of empagliflozin on erythropoietin levels, iron stores and red blood cell morphology in patients with type 2 diabetes and coronary artery disease. Circulation 2019;141:704-7. DOI: https://doi.org/10.1161/CIRCULATIONAHA.119.044235
Ghanim H, Abuaysheh S, Hejna J, et al. 2020. Dapagliflozin suppresses hepcidin and increases erythropoiesis. J Clin Endocrinol Metab 2020;105:e1056-63. DOI: https://doi.org/10.1210/clinem/dgaa057

How to Cite

Seidita, A., Mandreucci, F., Pistone, M., Calderone, S., Giuliano, A., Chiavetta, M., Giannitrapani, L., Citarrella, R., Soresi, M., Licata, A., Carroccio, A., & Compagnoni, S. (2024). Sodium-glucose cotransporter 2 inhibition in patients with liver cirrhosis and diabetes: a possible role in ascites control?. Italian Journal of Medicine, 18(4). https://doi.org/10.4081/itjm.2024.1829
Copyright (c) 2024 the Author(s) Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.